Home » Newsletters » BioWorld Science

BioWorld Science

Aug. 29, 2016

View Archived Issues

NIAID grant supports Navigen's development of depot formulation for treatment and prevention of HIV

Bristol Myers Squibb synthesizes potent and selective FXIa inhibitors

Phase III trial of BioChaperone PDGF for diabetic foot ulcer does not meet the primary endpoint

FDA issues EUA for Roche PCR Zika test, updates blood donation screening guidance

Xeloda approved for additional indication of adjuvant chemotherapy for rectal cancer

Cardiac biomarker responses seen with NEOD-001 in AL amyloidosis patients

Japanese orphan drug designation awarded to emicizumab in hemophilia A

F-star and Denali enter collaborative agreement to develop a multispecific antibody platform

AM-0466 described as a potent and selective Nav1.7 inhibitor with analgesic efficacy in vivo

Treakisym approved in Japan for the additional indication of chronic lymphocytic leukemia

Valixa approved in Japan for CMV prevention in organ transplant patients

Bristol Myers Squibb identifies BMS-212 as potent, liver-selective GK activator

Cell Medica collaborates with UCL on modified TCR products for the treatment of cancer

Enzymes in the kynurenine pathway linked to suicide risk

Ferring signs licensing agreement with Seikagaku for condoliase

Arog initiates phase III trial of crenolanib for advanced GIST

Bristol-Myers Squibb initiates phase I trial of BMS-986195

Piramal Enterprises discloses GPR120 agonists

FDA grants orphan drug designation to Gilead's ambrisentan/tadalafil combination

Sage Therapeutics patents GABA (A) receptor modulators

Japanese approval sought for Vimpat monotherapy for partial onset seizures

Ginkgo Pharmaceutical describes novel nucleoside derivatives

Sorrento Therapeutics discloses anti-HER2 antibody-dolastatin derivative conjugates

Spotlight Innovation enters sponsored research agreement with FSU to treat Zika infection

Trillium Therapeutics discovers bromodomain-containing protein inhibitors

BARDA awards USD 5.3 million to SAB Biotherapeutics for MERS treatment testing

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 16, 2026.
Precision psychiatry beyond, or before, biomarkers
BioWorld
There is broad agreement that psychiatric diagnoses in their current form are not reflective of any underlying biology, and that this is one of the things...
Keros reports beneficial effects of RKER-065 in ALS model
BioWorld Science
Keros Therapeutics Inc. has presented data regarding their activin receptor ligand trap, RKER-065, for the inhibition of the activin/myostatin signaling axis.
News in brief
BioWorld Asia
BioWorld Asia briefs for March 10, 2026
First-in-class POLG activator restores mtDNA across mutations
BioWorld Science
Researchers from Pretzel Therapeutics Inc. presented preclinical data of PX-578, a first-in-class POLG activator aimed at restoring mtDNA replication and...